EPISODE · Nov 2, 2015 · 55 MIN
SID 0002 Myriad Genetics
from Stocks-in-Depth
In Myriad's analyst day in NYC on September 14, 2015, management discussed the outlook for several new growth drivers, and it addressed challenges faced in its legacy BRCA1/2 hereditary cancer genetic testing franchise. We explore what's new, the ins and outs of each opportunity, and delve into the intricacies of companion diagnostics.
Embed this episode
Ready to play
SID 0002 Myriad Genetics
0:00
55:30
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Stocks-in-Depth?
This episode is 55 minutes long.
When was this Stocks-in-Depth episode published?
This episode was published on November 2, 2015.
Can I download this Stocks-in-Depth episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!